Aurobindo Pharma Ltd has received USFDA approval to manufacture and market Isosulfan Blue injection. The approved Abbreviated New Drug Application (ANDA) is bioequivalent and therapeutically equivalent to the reference listed drug product, Lymphazurin injection, of Covidien. It is used in the lymphography procedure in cardio-vascular therapeutics. The product has an estimated market size of USD 57 million for the 12 months ending December 2015.
Company Profile : Aurobindo Pharma Ltd
Leave a Reply